FluGen, Inc. is focused on developing a more effective influenza vaccine through its innovative M2SR (M2 Deleted Single Replication) vaccine platform. This platform aims to address significant challenges associated with current influenza vaccines, such as limited efficacy, short duration of immune responses, and ineffectiveness against drifted strains. The M2SR vaccine is a live, intranasal vaccine that stimulates a comprehensive immune response, including mucosal, humoral, and cellular immunity. It has shown promise in clinical trials, demonstrating robust safety and immunogenicity profiles, particularly in vulnerable populations like children and the elderly. The vaccine's unique mechanism allows it to provide protection against various strains of the virus, even when they undergo genetic drift.

In addition to its primary focus on influenza, FluGen is exploring the potential of the M2SR platform for broader applications, including the development of a combined COVID-19 and influenza vaccine. This dual-purpose vaccine aims to overcome the limitations of existing COVID-19 vaccines by providing longer-lasting immunity and protection at the site of infection. By incorporating the receptor binding domain of the SARS-CoV-2 spike protein into the M2SR framework, FluGen seeks to elicit strong immune responses against both viruses. The company's ongoing research and clinical trials reflect its commitment to advancing vaccine technology and improving public health outcomes in the face of respiratory diseases.

United States

FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases.

FluGen, Inc.

Company Details